EMA-approved Remsima™ could reduce cost of treating Crohn’s disease

Celltrion Healthcare has announced data demonstrating the healthcare savings achievable by using Remsima™ (CT-P13), a biosimilar monoclonal antibody infliximab, to treat patients with Crohn’s disease (CD) in France, Italy and the UK. (1)

Source: Pharmacy Europe - February 20, 2015 Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Biosimilars Practical therapeutics Industry News mAbs Gastroenterology Patient care biosimilar monoclonal antibody crohn's disease Latest News Remsima Source Type: news